RARE

Ultragenyx

RARE, USA

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for the treatment of long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidates that are in Phase 3 clinical trials include UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; and GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome. It also develops UX701 that is in Phase 2 clinical trial for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; GeneTx; Mereo; University of Pennsylvania; Solid Biosciences Inc.; Regeneron; Abeona; and Arcturus Therapeutics Holdings Inc. The company was incorporated in 2010 and is headquartered in Novato, California.

https://www.ultragenyx.com

Stock Price

$ 0.00

0% increase compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
RARE
stock
RARE

Why Shares of USA Rare Earth Are Tanking Today The Motley Fool

Read more →
RARE
stock
RARE

USA Rare Earth Stock (NASDAQ: USAR) Drops on Dec. 15, 2025: Latest News, Analyst Forecasts, and Key Catalysts Driving Volatility ts2.tech

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

STRONG BUY

Target Price:

$81.85

Analyst Picks

Strong Buy

13

Buy

6

Hold

1

Sell

0

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very High

394.66

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

-1,969.79 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-15.16 %

Low ≤ 2%

High ≥ 10%

Free Cash Flow - Revenue % (FCF)

-

Very Low

-57.96 %

Low ≤ 5%

High ≥ 15%

Debt to Equity

-

Very Low

128.21

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 84.97% of the total shares of Ultragenyx

1.

Vanguard Group Inc

(10.598%)

since

2025/06/30

2.

BlackRock Inc

(6.4917%)

since

2025/06/30

3.

Sands Capital Management, LLC

(4.092%)

since

2025/06/30

4.

JPMorgan Chase & Co

(3.3836%)

since

2025/06/30

5.

T. Rowe Price Associates, Inc.

(2.9949%)

since

2025/06/30

6.

Vanguard Total Stock Mkt Idx Inv

(2.9174%)

since

2025/07/31

7.

Baker Bros Advisors LP

(2.8771%)

since

2025/06/30

8.

FMR Inc

(2.7026%)

since

2025/06/30

9.

State Street Corp

(2.6691%)

since

2025/06/30

10.

Sands Capital Select Growth TE Inst EQ

(2.4793%)

since

2025/06/30

11.

Suvretta Capital Management, LLC

(2.3638%)

since

2025/06/30

12.

Vanguard Small Cap Index

(2.2609%)

since

2025/07/31

13.

ClearBridge Advisors, LLC

(2.2212%)

since

2025/06/30

14.

Federated Hermes Inc

(2.1267%)

since

2025/06/30

15.

Vanguard Explorer Inv

(2.1085%)

since

2025/06/30

16.

Wellington Management Company LLP

(1.9423%)

since

2025/06/30

17.

Geode Capital Management, LLC

(1.7774%)

since

2025/06/30

18.

RTW INVESTMENTS, LLC

(1.7717%)

since

2025/06/30

19.

Pictet Asset Manangement SA

(1.7639%)

since

2025/06/30

20.

Alkeon Capital Management, LLC

(1.7492%)

since

2025/06/30

21.

Strategic Advisers Fidelity US TtlStk

(1.7358%)

since

2025/07/31

22.

Deutsche Bank AG

(1.7286%)

since

2025/06/30

23.

JPMorgan Mid Cap Growth I

(1.7071%)

since

2025/07/31

24.

Adage Capital Partners Gp LLC

(1.5871%)

since

2025/06/30

25.

BNP Paribas Investment Partners SA

(1.5068%)

since

2025/06/30

26.

Alyeska Investment Group, L.P.

(1.4833%)

since

2025/06/30

27.

JPM US Mid Cap Growth-Composite

(1.278%)

since

2025/06/30

28.

Vanguard Small Cap Growth Index Inv

(1.2767%)

since

2025/07/31

29.

DWS Vermögensbildungsfonds I LD

(1.2248%)

since

2025/07/31

30.

Federated Hermes Kaufmann Small Cap A

(1.1321%)

since

2025/06/30

31.

Federated Hermes Kaufmann Small Cap Grow

(1.1321%)

since

2025/06/30

32.

Vanguard Institutional Extnd Mkt Idx Tr

(1.0554%)

since

2025/07/31

33.

SPDR® S&P Biotech ETF

(1.0276%)

since

2025/08/31

34.

Federated Hermes Kaufmann R

(0.9676%)

since

2025/06/30

35.

Federated Hermes Kaufmann Growth

(0.9676%)

since

2025/06/30

36.

ACAP Strategic A

(0.8578%)

since

2025/06/30

37.

Vanguard Strategic Equity Inv

(0.8121%)

since

2025/06/30

38.

Touchstone Sands Capital Select Growth Z

(0.7727%)

since

2025/06/30

39.

Fidelity Select Biotechnology

(0.7165%)

since

2025/07/31

40.

BNP Paribas Health Cr Innovtr Cl Cap

(0.7064%)

since

2025/07/31

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

—

EPS Estimate

—

Latest Release

Date

2025-09-30

EPS Actual

-1.81

EPS Estimate

-1.21

EPS Difference

-0.6

Surprise Percent

-49.5868%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Weak Deep Value(2)
Defensive
Moderately Defensive(5.5)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(3.8)
GARP
Not Attractive for GARP(1)
Growth
Weak Growth Prospect(1)
Momentum
Moderate Momentum(3.5)
Net Net
Not Undervalued (Net-Net)(1)
Quality
Low Quality Business(1.5)
Value
Overpriced(2)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.